National Changhua University of Education Institutional Repository : Item 987654321/15547

English | 正體中文 | 简体中文 | Items with full text/Total items : 6507/11669
Visitors : 30069500 Online Users : 637

RC Version 3.2 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.

Scope Adv. Search

Login ‧ Upload ‧ Help ‧ About ‧ Administer

NCUEIR > College of Science > Department of Biology > Periodical Articles > Item 987654321/15547

Please use this identifier to cite or link to this item: http://ir.ncue.edu.tw/ir/handle/987654321/15547

Title:	Consistent Sequence Variation of Epstein-Barr Virus Nuclear Antigen 1 in Primary Tumor and Peripheral Blood Cells of Patients with Nasopharyngeal Carcinoma
Authors:	Wang, Wen-Yi;Chien, Yi-Chih;Jan, Jian-Sheng;Chueh, Chun-Mei;Lin, Jin-Ching
Contributors:	生物學系
Date:	2002-08
Issue Date:	2013-02-05T03:06:57Z
Publisher:	American Association for Cancer Research
Abstract:	Purpose: Nasopharyngeal carcinoma (NPC) has been provenas a cancer associated with Epstein-Barr virus (EBV). This study was performed to examine sequence variations of the EBV nuclear antigen 1 gene (EBNA-1) in primary tumor and peripheral-blood cells of NPC patients from Taiwan. Experimental Design: DNA extracted from freshly frozen tumor tissues and corresponding peripheral-blood cells of 13 previously untreated NPC patients were subjected to PCR and direct sequencing using EBNA-1-specific primers. We compared the sequence data and analyzed the clinical outcomes. Results: We obtained a 100% positive-detection rate of EBV DNA in the primary tumors of all patients irrespective of the degree of differentiation. The EBNA-1 gene of all tumor samples was the “V-val” strain, showing the same clustered point mutations. They included 21 nucleotide exchanges, leading to 14 amino-acid mutations and 6 silent exchanges, relative to B95-8 cell line. Two of 13 tumors exhibited an additional point mutation at codon 585. EBV DNA was also detected in peripheral-blood cells of 9 of 13 patients under our experimental conditions. Direct-sequencing data showed match alterations of EBNA-1 gene between the primary tumor and peripheral-blood cells. Tumor relapse was observed in four of nine patients with detectable EBNA-1 DNA in their peripheral-blood cells, whereas none of the four patients without detectable EBNA-1 DNA in their peripheral-blood cells developed tumor relapse. Conclusions: Results of the current study represents the first demonstration of consistent sequence variation of EBNA-1 in primary tumors and peripheral-blood cells. Clinical observations support that the presence of EBV DNA in the peripheral-blood cells may arise from disseminated cancer cells, resulting in a higher relapse rate and poor prognosis.
Relation:	Clinical Cancer Research, 8(8): 2586-2590
Appears in Collections:	[Department of Biology] Periodical Articles

Files in This Item:

File	Size	Format
index.html	0Kb	HTML	548	View/Open

Loading...